WEDNESDAY, Dec. 23, 2020 -- Multicomponent cognitive behavioral therapy is strongly recommended for the treatment of chronic insomnia in adults, according to a new clinical practice guideline issued by the American Academy of Sleep Medicine and published online Nov. 9 in the Journal of Clinical Sleep Medicine.
Jack D. Edinger, Ph.D., from National Jewish Health in Denver, and colleagues conducted a systematic literature review to evaluate the relevant literature and quality of evidence to develop recommendations for behavioral and psychological treatments for chronic insomnia disorder in adults.
The authors strongly recommend that clinicians use multicomponent cognitive behavioral therapy for treatment of chronic insomnia disorder in adults. Conditional recommendations include use of stimulus control, sleep restriction therapy, and relaxation therapy as single-component therapies for treatment of chronic insomnia disorder in adults. Sleep hygiene is not recommended for use as a single-component therapy for treatment of chronic insomnia disorder.
"Although sleep hygiene practices are often suggested and well understood by patients, sleep hygiene [recommendations] do not constitute an effective stand-alone therapy," Edinger said in a statement.
Several authors disclosed financial ties to the pharmaceutical and medical technology industries.
Abstract/Full Text (subscription or payment may be required)
© 2020 HealthDay. All rights reserved.
Posted: December 2020
THURSDAY, Dec. 10, 2020 -- Sleep-related impairment among physicians is associated with increased burnout, decreased professional fulfillment, and increased self-reported...
TUESDAY, Dec. 1, 2020 -- Among individuals with dementia, higher-dose Z-drug use is associated with an increased risk for fractures, falls, and ischemic stroke, according to a...
TUESDAY, Nov. 17, 2020 -- For individuals who have recovered from the acute phase of COVID-19, postviral fatigue is prevalent and is not associated with COVID-19 severity,...
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.